Klotho Neurosciences (KLTO)announced that its Letter of Intent, or LoI, with Turn Biotechnologies was allowed to expire by the parties. Following careful evaluation, Klotho’s Board of Directors determined that the proposed transaction did not fit its long-term strategic plan. Instead, the Company will focus its resources on advancing its Klotho anti-aging protein research pipeline and development of treatments, where it sees the greatest opportunity to deliver value for patients and shareholders.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KLTO:
- Klotho Neurosciences to acquire select assets from Turn Biotechnologies
- Klotho Neurosciences Faces Nasdaq Delisting Notice
- Klotho Neurosciences Delays Quarterly Report Filing
- Klotho Neurosciences Partners with AAVnerGene for Gene Therapy
- Klotho Neurosciences signs KLTO-202 manufacturing, development agreement